Strategic acquisitions Solabia has actively expanded through acquisitions in 2026, including Mibelle Biochemistry and Xebios Diagnostics, signaling a growth-oriented strategy that opens up cross-sell opportunities for cosmetics actives, nutraceuticals, and microbiological diagnostics.

Cosmetics and life sciences synergy With strong positions in cosmetics actives, microbiology, and diagnostics, Solabia can partner to co-develop or bundle high-value ingredients and testing services for personal care brands seeking integrated solution pipelines.

Global R&D capability A large R&D network of international researchers skilled in biocatalysis, enzymatic synthesis, fermentation, and plant extraction enables rapid translation of customer needs into novel actives, offering a compelling value proposition for premium formulations.

CSR and sustainability appeal Solabia positions CSR and sustainable development as a core priority, presenting a sales lever for clients aiming to meet ESG goals, regulatory compliance, and green product claims in cosmetics, pharma, and nutrition.

Center of innovation Recent investments in a new center and expansion of capabilities suggest enhanced client experience and capability demonstrations, creating opportunities for hands-on trials, co-creation, and larger multi-site contracts.